TYK2 and rheumatoid arthritis: Tofacitinib is a JAK1/3 inhibitor, with less efficacy vs. JAK2 and TYK2, and it is approved for the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis (164).